Controversies in Cushing’s Syndrome/Cushing’s Disease (CS/CD) Diagnosis and Management
Image For Activity Cover
Expires on Dec 31, 2024
Credit Offered
1 AMA PRA Category 1 Credit
1 ABIM-MOC Point
1 Participation Credit
  • Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended

During this symposium, our expert faculty utilize case based discussions to review the standard of care and current practice for treating patients with Cushing’s Disease. Faculty will review and discuss individualized treatment strategies for both mild and severe hypercortisolism and instruct on best practices for managing patients during periods of high stress or illness.

Pituitary specialists and PGA specialty group including physicians, physician assistants, and other allied healthcare professionals treating patients with CS/CD.

Upon completion of this activity, participants will be better able to:

  • Plan individualized treatment strategies and effectively treat patients with
    • mild hypercortisolism
    • severe hypercortisolism
  • Execute management plans for patients with CS/CD during illness or periods of high stress
  • Determine optimal labs for use to screen and monitor patients with hypercortisolism/CS/CD

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and CMM Global. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit

Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

For questions about content or obtaining CME credit, please contact the Endocrine Society at

Maria Fleseriu, MD, FACE – Program Chair
Oregon Health & Science University – Portland, OR, USA
Portland, OR

Beverly Biller, MD
Massachusetts General Hospital

Boston, MA

Irina Bancos, MD           
Mayo Clinic College of Medicine
Rochester, MN

Michael Buchfelder, MD, PhD
University of Erlangen Hospital
Erlangen, Germany       

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

  • Maria Fleseriu, MD, FACE: Amryt – Scientific Consultant, Grant Recipient; Ascendis - Scientific Consultant, Grant Recipient; HRA Pharma - Scientific Consultant; Ispen - Scientific Consultant; Novo Nordisk - Scientific Consultant; Pfizer - Scientific Consultant; Recordati, Inc - Scientific Consultant, Grant Recipient;  Xeris - Scientific Consultant, Grant Recipient; Crinetics - Grant Recipient.  

  • Beverly Biller. MD – Ascendis – Research Grant; Crinetics – Research Grant, Consultant; Ionis – Research Grant; Amryt - Consultant; Camurus - Consultant; Diurnal - Consultant; HRA Pharma - Consultant; Neurocrine - Consultant; Novo Nordisk - Consultant; Recordati - Consultant; Sparrow - Consultant; Xeris – Consultant.

  • Irina Bancos, MD: HRA Pharma – Consulting, Advisory Board; Corcept - Consulting, Advisory Board; Sparrow Pharmaceutics -  Consulting; Recordati – Consulting, Advisory Board, Investigator Award; Adrenas – Data Safety Monitoring Boards; Elsevier  - Writer; Dynamed – Reviewer; NIH – Investigator Award; Endocrine Society Educational Initiatives

  • Michael Buchfelder, MD: Corcept, grants for MR reading, to the University Hospital erlangen, Germany
    Strongbridge Biopharm, grants for MR reading to the University Hospital Erlangen
    Crinetics, Consultant agreement exists, as yet no function and no fees received 

The following faculty reported no relevant financial relationships:

The following member who reviewed content for this activity reported relevant financial relationships:
Ismat Shafiq, MD  

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

This educational activity is supported by an educational grant from Recordati Rare Diseases, Inc.
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
Android App Download IOS App Download Powered By